Global Anti-Infective Drugs Market Analysis
Infectious diseases are health disorders caused by the invasion and multiplication of foreign organisms that cause infection in the host body. The growth and multiplication of harmful pathogens like parasites, fungi, viruses, and bacteria cause major infections in the host body. Infection is spread through an infected object, airborne particles, body fluids, or skin contact. Anti-infective drugs are used to treat infectious diseases or conditions. Anti-infective drugs work by inhibiting growth or removing infectious agents.
Global Anti-Infective Drugs Market: Drivers
Key players in the market focus on the launch of new products, which is expected to drive the growth the global anti-infective drugs market. For example, Melinta Therapeutics, Inc. launched intravenous and oral formulations of Baxdela (Delafloxacin) in January 2018 in the U.S. Buxdela is used for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) caused by gram-positive bacteria and gram-negative bacteria.
Furthermore, the growing prevalence of sepsis is expected to drive growth of the anti-infective drugs market. Sepsis is a life-threatening condition caused by the body’s response to infection. For example, according to the World Health Organization (WHO) report, in 2018, more than 30 million people worldwide are affected by sepsis, resulting in 6 million deaths each year. In addition, 3 million newborns and 1.2 million children suffer from sepsis each year.
๐๐จ ๐๐๐ญ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ฉ๐จ๐ซ๐ญ ๐ฐ๐ข๐ญ๐ก ๐๐๐ญ๐๐ฌ๐ญ ๐๐จ๐ฏ๐ข๐๐๐ ๐๐ฆ๐ฉ๐๐๐ญ ๐๐ง๐๐ฅ๐ฒ๐ฌ๐ข๐ฌ @ https://www.coherentmarketinsights.com/insight/request-sample/2489
Moreover, the growing number of pipeline studies to develop anti-infective drugs for the treatment of rare infectious diseases is contributing to the growth of the global anti-infective drugs market. For example, the National Institute of Allergy and Infectious Diseases (NIAID) launched a clinical trial in January 2019 to study the safety and efficacy of four drugs i.e. REGN-EB3, MAb114, Remdesivir, ZMapp, in people with the Ebola virus. The study is expected to be completed by November 2024.
Although, hypersensitivity reactions related to the administration of anti-infective drugs are expected to hinder the growth of the global anti-infective drugs market. For example, Clinical Infectious Diseases reported in 2013 that in a study of the prevalence of self-reported antibiotic allergies, 9.0% of the 411,543 outpatients in their medical records in San Diego County, California, had penicillin allergy.
Global Anti-Infective Drugs Market: Regional Analysis
The global anti-infective drugs market in North America is expected to grow significantly during the estimated period. This is due to the increasing expansion activities of the major players in the region. For example, Xellia Pharmaceuticals, a specialized pharmaceutical company that offers anti-infective drugs against serious and often life-threatening infections, opened its new office in September 2018 in Buffalo Grove, near Chicago, Illinois, to expand its sales and production capabilities within the U.S.
Moreover, the global anti-infective drugs market is expected to grow significantly in the estimated period as new products are launched in the region in Asia Pacific. For example, Astellas Pharma Inc. launched Dafclir Tablets 200 mg (fidaxomicin) in September 2018 for the treatment of infectious enteritis (including pseudomembranous colitis) in Japan. Astelles has signed an agreement with Merck for the development and marketing of Dafclir in Japan in 2018.
๐๐จ ๐๐๐ญ ๐๐๐ฌ๐๐๐ซ๐๐ก ๐๐๐ ๐๐ซ๐จ๐๐ก๐ฎ๐ซ๐ ๐๐๐ซ๐ @ https://www.coherentmarketinsights.com/insight/request-pdf/2489
Global Anti-Infective Drugs Market- Segmentation
On the basis of Drug Class Type, the Global Anti-Infective Drugs Market is segmented into:
- Anti-viral Drugs
- Anti-fungal Drugs
- Polyenes
- Echinocandins
- Azoles
- Others
- Anti-bacterial Drugs
- Aminoglycoside
- Tetracycline
- Macrolides
- Quinolones
- B-Lactams
- Others
On the basis of Indication Type, the Global Anti-Infective Drugs Market is segmented into:
- Respiratory Virus Infection
- HIV Infection
- Hepatitis Virus Infection
- Candidiasis
- Aspergillosis
- Dermatophytosis
- Tuberculosis
- Sepsis
- Methicillin-resistant Staphylococcus Aureus (MRSA)
- Pneumonia
- Others
On the basis of Route of Administration, the Global Anti-Infective Drugs Market is segmented into:
- Parenteral
- Topical
- Oral
On the basis of Distribution Channel, the Global Anti-Infective Drugs Market is segmented into:
- Online Pharmacy
- Retail Pharmacy
- Hospital Pharmacy
On the basis of Region, the Global Anti-Infective Drugs Market is segmented into:
- Africa
- Middle East
- Latin America
- Asia Pacific
- Europe
- North America
Global Anti-Infective Drugs Market- Competitive Landscape
Key players operating in the global anti-infective drugs market include, Abbott Laboratories, Alcon Pharmaceuticals Ltd., Astellas Pharma Inc., AstraZeneca Plc., Bayer HealthCare AG, Alkem Labs, Pacific India Pharma Limited, Pfizer, and others.
๐๐ฎ๐ฒ ๐๐จ๐ฐ ๐๐ง๐ ๐๐๐ญ ๐ ๐ฅ๐๐ญ ๐๐๐ ๐๐๐๐ ๐๐ ๐
๐๐ฎ๐ซ๐๐ก๐๐ฌ๐ ๐๐ก๐ข๐ฌ ๐๐ซ๐๐ฆ๐ข๐ฎ๐ฆ ๐๐๐ฉ๐จ๐ซ๐ญ ๐๐จ ๐๐๐๐๐ฌ๐ฌ ๐ ๐ฎ๐ฅ๐ฅ ๐๐ง๐๐จ๐ซ๐ฆ๐๐ญ๐ข๐จ๐ง @ https://www.coherentmarketinsights.com/promo/buynow/2489
About Us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact Us:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837